PE20230601A1 - Pirrolopirimidinaminas como inhibidores del sistema del complemento - Google Patents
Pirrolopirimidinaminas como inhibidores del sistema del complementoInfo
- Publication number
- PE20230601A1 PE20230601A1 PE2022002121A PE2022002121A PE20230601A1 PE 20230601 A1 PE20230601 A1 PE 20230601A1 PE 2022002121 A PE2022002121 A PE 2022002121A PE 2022002121 A PE2022002121 A PE 2022002121A PE 20230601 A1 PE20230601 A1 PE 20230601A1
- Authority
- PE
- Peru
- Prior art keywords
- alkyl
- complement system
- independently
- inhibitors
- union
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
- C07D471/14—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D473/00—Heterocyclic compounds containing purine ring systems
- C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
- C07D473/16—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D473/00—Heterocyclic compounds containing purine ring systems
- C07D473/26—Heterocyclic compounds containing purine ring systems with an oxygen, sulphur, or nitrogen atom directly attached in position 2 or 6, but not in both
- C07D473/32—Nitrogen atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D473/00—Heterocyclic compounds containing purine ring systems
- C07D473/26—Heterocyclic compounds containing purine ring systems with an oxygen, sulphur, or nitrogen atom directly attached in position 2 or 6, but not in both
- C07D473/32—Nitrogen atom
- C07D473/34—Nitrogen atom attached in position 6, e.g. adenine
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
- C07D498/14—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Psychiatry (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Ophthalmology & Optometry (AREA)
- Pulmonology (AREA)
- Diabetes (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Hospice & Palliative Care (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Saccharide Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Abstract
Refiere a compuestos de formula (I), o sales farmaceuticamente aceptables de los mismos, que son inhibidores del sistema del complemento, en donde X es una union o C(RX)2; Y es una union, C(RY )2, o -N(Rb) -; G es S o C(R3)2; Ra y Rb son independientemente H o (C1-C6)alquilo; R1 se sustituye opcionalmente con alquenilo, cicloalquenilo entre otros; R2 representa heteroarilo biciclico o triciclico opcionalmente sustituido; R3 es independientemente (C1- C6)alcoxi, (C1-C6)alquilo, entre otros, o dos instancias vecinales, geminales y hominales junto con un atomo de carbono, forman un (C3-C7)cicloalquilo; RX y RY son H, (C1-C6)alquilo, o (C3-C7)cicloalquilo; R13 y R14 representan independientemente haloalquilo, heteroarilo, entre otros. Asimismo, refiere a composiciones farmaceuticas que comprenden el compuesto, o una sal de este, y un vehiculo farmaceuticamente aceptable, para tratar o prevenir una enfermedad o condicion caracterizada por la actividad aberrante del sistema del complemento, seleccionados del grupo que consiste en vasculitis asociada a anticuerpos contra el citoplasma de neutrofilos (ANCA) (AAV), sindrome de Guillain-Barre, enfermedad de Crohn, entre otros.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063004799P | 2020-04-03 | 2020-04-03 | |
| PCT/US2021/025547 WO2021202977A1 (en) | 2020-04-03 | 2021-04-02 | Pyrrolopyrimidine amines as complement inhibitors |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PE20230601A1 true PE20230601A1 (es) | 2023-04-10 |
Family
ID=77929437
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PE2022002121A PE20230601A1 (es) | 2020-04-03 | 2021-04-02 | Pirrolopirimidinaminas como inhibidores del sistema del complemento |
Country Status (22)
| Country | Link |
|---|---|
| US (1) | US20230159536A1 (es) |
| EP (1) | EP4125914A1 (es) |
| JP (1) | JP2023519824A (es) |
| KR (1) | KR20220163955A (es) |
| CN (1) | CN115427044A (es) |
| AR (1) | AR121715A1 (es) |
| AU (1) | AU2021246098A1 (es) |
| BR (1) | BR112022018067A2 (es) |
| CA (1) | CA3176808A1 (es) |
| CL (1) | CL2022002649A1 (es) |
| CO (1) | CO2022015630A2 (es) |
| CR (1) | CR20220553A (es) |
| CU (1) | CU20220060A7 (es) |
| DO (1) | DOP2022000211A (es) |
| EC (1) | ECSP22085221A (es) |
| IL (1) | IL296978A (es) |
| JO (1) | JOP20220227A1 (es) |
| MX (1) | MX2022012056A (es) |
| PE (1) | PE20230601A1 (es) |
| TW (1) | TW202204358A (es) |
| UY (1) | UY39150A (es) |
| WO (1) | WO2021202977A1 (es) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA3234428A1 (en) * | 2021-10-18 | 2023-04-27 | Nader Najafian | Use of complement factor d inhibitor for treatment of lupus nephritis and immunoglobulin a nephropathy |
| WO2024008121A1 (zh) * | 2022-07-06 | 2024-01-11 | 南京明德新药研发有限公司 | 二氟取代的氮杂双环化合物及其应用 |
| WO2024047078A1 (en) * | 2022-09-01 | 2024-03-07 | F. Hoffmann-La Roche Ag | Dosage regimen of vicasinabin |
| US11945818B1 (en) | 2023-09-06 | 2024-04-02 | King Faisal University | Pyrrolo[3,2-c]quinoline compounds as CK2 inhibitors |
| US11964981B1 (en) | 2023-09-18 | 2024-04-23 | King Faisal University | Substituted pyrimido[4,5-b]indoles as CK2 inhibitors |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EA023259B1 (ru) * | 2011-01-04 | 2016-05-31 | Новартис Аг | Индольные соединения или их аналоги, полезные для лечения возрастной макулярной дегенерации (amd) |
-
2021
- 2021-03-31 AR ARP210100817A patent/AR121715A1/es unknown
- 2021-04-01 TW TW110112139A patent/TW202204358A/zh unknown
- 2021-04-02 JO JOP/2022/0227A patent/JOP20220227A1/ar unknown
- 2021-04-02 JP JP2022556491A patent/JP2023519824A/ja active Pending
- 2021-04-02 EP EP21781014.2A patent/EP4125914A1/en active Pending
- 2021-04-02 KR KR1020227033595A patent/KR20220163955A/ko active Search and Examination
- 2021-04-02 CU CU2022000060A patent/CU20220060A7/es unknown
- 2021-04-02 CA CA3176808A patent/CA3176808A1/en active Pending
- 2021-04-02 BR BR112022018067A patent/BR112022018067A2/pt unknown
- 2021-04-02 IL IL296978A patent/IL296978A/en unknown
- 2021-04-02 MX MX2022012056A patent/MX2022012056A/es unknown
- 2021-04-02 CR CR20220553A patent/CR20220553A/es unknown
- 2021-04-02 PE PE2022002121A patent/PE20230601A1/es unknown
- 2021-04-02 AU AU2021246098A patent/AU2021246098A1/en active Pending
- 2021-04-02 CN CN202180025930.0A patent/CN115427044A/zh active Pending
- 2021-04-02 US US17/915,179 patent/US20230159536A1/en active Pending
- 2021-04-02 WO PCT/US2021/025547 patent/WO2021202977A1/en active Application Filing
- 2021-04-05 UY UY0001039150A patent/UY39150A/es unknown
-
2022
- 2022-09-28 DO DO2022000211A patent/DOP2022000211A/es unknown
- 2022-09-28 CL CL2022002649A patent/CL2022002649A1/es unknown
- 2022-10-31 CO CONC2022/0015630A patent/CO2022015630A2/es unknown
- 2022-11-02 EC ECSENADI202285221A patent/ECSP22085221A/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CR20220553A (es) | 2023-02-03 |
| CN115427044A (zh) | 2022-12-02 |
| WO2021202977A1 (en) | 2021-10-07 |
| KR20220163955A (ko) | 2022-12-12 |
| TW202204358A (zh) | 2022-02-01 |
| AR121715A1 (es) | 2022-06-29 |
| US20230159536A1 (en) | 2023-05-25 |
| IL296978A (en) | 2022-12-01 |
| CU20220060A7 (es) | 2023-05-11 |
| CO2022015630A2 (es) | 2022-11-29 |
| UY39150A (es) | 2021-10-29 |
| JOP20220227A1 (ar) | 2023-01-30 |
| JP2023519824A (ja) | 2023-05-15 |
| CA3176808A1 (en) | 2021-10-07 |
| BR112022018067A2 (pt) | 2022-10-25 |
| CL2022002649A1 (es) | 2023-05-26 |
| AU2021246098A1 (en) | 2022-10-20 |
| MX2022012056A (es) | 2022-10-13 |
| DOP2022000211A (es) | 2022-11-15 |
| ECSP22085221A (es) | 2022-12-30 |
| EP4125914A1 (en) | 2023-02-08 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PE20230601A1 (es) | Pirrolopirimidinaminas como inhibidores del sistema del complemento | |
| PE20230249A1 (es) | Compuestos de heteroarilo biciclicos y usos de estos | |
| AR119731A1 (es) | Inhibidores del inflamasoma nlrp3 | |
| PE20211655A1 (es) | Compuestos de 6-azabencimidazol sustituidos como inhibidores de hpk1 | |
| PE20191260A1 (es) | Compuestos inhibidores del vih | |
| AR089019A1 (es) | Derivados modificados de 4-fenil-piridina | |
| AR108812A1 (es) | Proceso para preparar un derivado de piridona policíclica sustituida y cristal del mismo | |
| DOP2018000187A (es) | Derivados de pirazolo[1,5-a]pirazin-4-ilo | |
| AR104417A2 (es) | Compuestos de tiadiazolidina, procedimiento para su preparación, composición farmacéutica que lo compone y usos de dichos compuestos | |
| MA45223B1 (fr) | Nouveaux dérivés de pipéridinyle subsitués par (hétéro)aryle, leur procédé de préparation et compositions pharmaceutiques les contenant | |
| AR083069A1 (es) | Analogos de nucleotidos sustituidos | |
| MA42230B1 (fr) | Dérivés bicycliques, leur procédé de préparation, et compositions pharmaceutiques les contenant | |
| PE20212306A1 (es) | Inhibidores de enpp1 y metodos para modular una respuesta inmunitaria | |
| MA42231B1 (fr) | Nouveaux dérivés d'hydroxyacide, leur procédé de préparation, et compositions pharmaceutiques les contenant | |
| MA42232B1 (fr) | Nouveaux dérivés d'acide aminé, leur procédé de préparation et compositions pharmaceutiques les contenant | |
| AR046297A1 (es) | Inhibidores de la dpp - iv metodos para prepararlos y composiciones farmaceuticas que los contienen como agente activo | |
| EA200970510A1 (ru) | Гетеромоноциклическое соединение и его применение | |
| EA201391775A1 (ru) | Производное азола, способ его получения, промежуточное соединение и химический агент, предназначенный для применения в сельском хозяйстве и садоводстве, и агент для защиты промышленных материалов | |
| AR105893A1 (es) | Derivados del anillo (hetero) aromático sustituidos con carboxi como inhibidores de xantina oxidasa y del transportador 1 del anión urato | |
| AR087915A1 (es) | N-(3-(2-amino-6,6-difluor-4,4a,5,6,7,7a-hexahidro-ciclopenta-[e][1,3]oxazin-4-il)-fenil)-amidas como inhibidores de la bace1 | |
| AR120174A1 (es) | Inhibidores del factor d del complemento para administración oral | |
| JP2019532067A5 (es) | ||
| PE20211769A1 (es) | Compuestos heteroaromaticos como inhibidores de vanina | |
| PE20240775A1 (es) | Compuestos antivirales | |
| PE20210478A1 (es) | Compuestos heteroaromaticos como inhibidores de vanina |